Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ANABthis companyAnaptysBio, Inc.	$47.82	-70.26×	24.14×	3.83×	9.73×	-639.3%	99.0%	20.4%	-5.6%	-35.6%	14.6%	2.2%	0.38×	-3.24×	0.6×	9.07×	0.0%	5	2.21	3	B
ACRSAclaris Therapeutics, Inc.	$4.22	-5.68×	3.58×	47.18×	-5.45×	-122.2%	73.3%	-975.9%	-829.6%	-63.0%	-57.7%	-12.8%	0.02×	0.28×	0×	5.28×	0.0%	2	-2.65	1	D+
ANNXAnnexon, Inc.	$4.27	-3.75×	3.68×	0×	-3.14×	-80.0%	0.0%	0.0%	0.0%	-97.7%	-91.0%	-24.0%	0.12×	0.66×	0×	5.68×	0.0%	1	-1.2	2	C
ARTVArtiva Biotherapeutics, Inc.	$4.21	-1.25×	0.95×	0×	-1.1×	-84.3%	0.0%	0.0%	0.0%	-76.3%	-74.9%	-75.7%	0.1×	0.19×	0×	8.61×	0.0%	1	4.66	2	C+
CNTBConnect Biopharma Holdings Limited	$0.75	-2.82×	3.74×	2,452.52×	-2.19×	-15.8%	100.0%	-90740.6%	-86687.5%	-132.2%	-135.7%	-32.9%	0.02×	0.69×	0×	3.74×	0.0%	2	-15.61	2	C+
DNTHDianthus Therapeutics, Inc.	$90.78	-9.81×	3.16×	764.98×	-9.31×	-101.9%	100.0%	-8739.3%	-7973.3%	-32.9%	-35.5%	-8.3%	0×	0.31×	0×	13.32×	0.0%	1	67.2	2	C
Peer median	—	-3.75×	3.58×	47.18×	-3.14×	-84.3%	73.3%	-975.9%	-829.6%	-76.3%	-74.9%	-24.0%	0.02×	0.31×	0×	5.68×	0.0%	1	-1.2	2	—